Analysis of GLP-1 receptor agonist effects on cancer outcomes examines whether these metabolic drugs influence cancer risk, progression, or mortality.
Key findingAnalysis of GLP-1 receptor agonist effects on cancer outcomes examines whether these metabolic drugs
What the researchers found
Analysis of GLP-1 receptor agonist effects on cancer outcomes examines whether these metabolic drugs influence cancer risk, progression, or mortality.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Network meta-analysis through December 2024 from four databases comparing individual GLP-1 drugs for comprehensive cardiovascular outcomes.
How the study worked
In publication.
Who was studied
Adults in cardiovascular RCTs comparing individual GLP-1 drugs through December 2024
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.
Diabetes, obesity & metabolism, 27(4), 1735-1751
Citation
An, Xuedong; Sun, WenJie; Wen, Zhige; Duan, LiYun; Zhang, YueHong; Kang, Xiaomin; Ji, Hangyu; Sun, Yuting; Jiang, Linlin; Zhao, Xuefei; Gao, Qing; Lian, Fengmei. (2025). Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.. Diabetes, obesity & metabolism, 27(4), 1735-1751. https://doi.org/10.1111/dom.16228